Q-omics provides the consensus-scored TPH1 profile across patient tissues and cancer cell-line models. TPH1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TPH1 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, TPH1 RNA expression shows 19,226 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, COAD, and UVM as cancer lineages where TPH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TPH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TPH1 survival associations across molecular data types. TPH1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TPH1 RNA expression–survival associations across cancer types. High TPH1 expression shows unfavorable associations in OV, but favorable associations in HNSC, BLCA, PAAD, LUAD and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TPH1 RNA expression.
This table summarizes TPH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TPH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TPH1 shows lower tumor expression in COAD, KICH, BLCA, READ and STAD and higher tumor expression in CHOL. The COAD box plot shows higher TPH1 RNA expression in normal versus tumor tissue (log2 FC = −2.001, t-test p < 0.001).
This table shows molecular features associated with TPH1 in patient tissues and cancer cell lines. In patient samples, TPH1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TPH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
